People | April 04, 2024
Max CMD Abhay Soi is new president of NATHEALTH
New leadership team announced at NATHEALTH Annual General Meeting 2024
New leadership team announced at NATHEALTH Annual General Meeting 2024
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Vivity is the first and only wavefront-shaping IOL with Alcon’s proprietary X-WAVE Technology
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Subscribe To Our Newsletter & Stay Updated
